Ross Osborn

“So, adjusted EBITDA came down by only $3 million, yet the free cash flow guide was cut by $10 million after a strong 3Q. So, I guess the question is, what accounts for the gap, and is the timing shift into 27 or a step down in the conversion rate we should carry forward?”

“So, to start off, there's been some confusion around how much nerve tape is incremental versus cannibalistic to your business, and we heard Lindsey's comments on 26% organic growth this year.”

“So following up on the prior line of questioning on Cincinnati, but with regards to the second half of next year and beyond, do you view the switching costs as high enough that we should view the $22 to $27 million of revenue as deferred, or should we expect accounts to convert?”

“I'm on the MedTech team here at Wells Fargo. And please introduce management from Integra. Joining us from the company is Lee Knight, CFO, and Michael McBrenn, the new Chief Commercial Officer.”

“I'm on the MedTech team here at Wells Fargo. We are joined by the management team of Globus Medical. With us is Keith Feil, President and CEO, as well as Brian Kearns, Corporate and IR.”